Trinity Biotech (TRIB) Receivables - Net (2016 - 2025)
Trinity Biotech's Receivables - Net history spans 12 years, with the latest figure at $9.4 million for Q4 2025.
- On a quarterly basis, Receivables - Net fell 30.22% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.4 million, a 30.22% decrease, with the full-year FY2025 number at $9.4 million, down 30.22% from a year prior.
- Receivables - Net hit $9.4 million in Q4 2025 for Trinity Biotech, down from $13.4 million in the prior quarter.
- Over the last five years, Receivables - Net for TRIB hit a ceiling of $2.7 billion in Q4 2022 and a floor of $1.3 million in Q4 2023.
- Historically, Receivables - Net has averaged $543.6 million across 5 years, with a median of $9.4 million in 2025.
- Biggest five-year swings in Receivables - Net: soared 90020.56% in 2022 and later tumbled 99.95% in 2023.
- Tracing TRIB's Receivables - Net over 5 years: stood at $3.0 million in 2021, then soared by 90020.56% to $2.7 billion in 2022, then tumbled by 99.95% to $1.3 million in 2023, then surged by 924.9% to $13.4 million in 2024, then crashed by 30.22% to $9.4 million in 2025.
- Business Quant data shows Receivables - Net for TRIB at $9.4 million in Q4 2025, $13.4 million in Q4 2024, and $1.3 million in Q4 2023.